Myd88 inhibitor and use thereof
By developing MyD88 inhibitors with specific structures to inhibit the MyD88 signaling pathway, the problem of the lack of effective inhibitors in existing technologies has been solved, enabling effective treatment of inflammation-related diseases, especially acute lung injury.
WO2026113987A1PCT designated stage Publication Date: 2026-06-04ZHEJIANG MEDICAL COLLEGE
Patent Information
- Authority / Receiving Office
- WO Β· WO
- Patent Type
- Applications
- Current Assignee / Owner
- ZHEJIANG MEDICAL COLLEGE
- Filing Date
- 2025-11-17
- Publication Date
- 2026-06-04
Smart Images
Figure CN2025135261_04062026_PF_FP_ABST
Abstract
The present invention relates to the field of pharmaceutical technology, and in particular, to a MyD88 inhibitor and use thereof. The MyD88 inhibitor comprises one or more of a specific compound of a novel structure and a racemate, optical isomer, pharmaceutically acceptable salt, pharmaceutically acceptable hydrate, pharmaceutically acceptable solvate, and pharmaceutically acceptable prodrug of the compound. The inhibitor can inhibit the excessive expression and release of inflammatory cytokines, thereby treating diseases associated with excessive inflammation via this pharmacological mechanism. Studies show that the MyD88 inhibitor provided herein has an effective inhibitory effect on inflammatory factors and better in vivo anti-inflammatory activity.
Need to check novelty before this filing date? Find Prior Art